Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ELAVL4, PARK10, and the Celts.

Kristoffer Haugarvoll1, Mathias Toft, Owen A Ross

  • 1Department of Neuroscience and Neurology, Mayo Clinic College of Medicine, Jacksonville, Florida, USA. haugarvoll.kristoffer@mayo.edu

Movement Disorders : Official Journal of the Movement Disorder Society
|January 19, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The EXPLAIN Study: Exploring Arthrogryposis Multiplex Congenita in Adults in Norway - A Description of Demographic, Medical, and Neurological Findings.

American journal of medical genetics. Part C, Seminars in medical genetics·2026
Same author

Biallelic inactivating variants in the chromatin remodeler DMAP1 cause a syndromic neurodevelopmental disorder.

The Journal of clinical investigation·2026
Same author

A homozygous splice-site variant in SAMHD1 shows variable expressivity of Aicardi-Goutières syndrome type 5: a case report and literature review.

Frontiers in pediatrics·2026
Same author

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset.

NPJ Parkinson's disease·2026
Same author

Evaluating impulse control disorders in people with Parkinson's disease: agreement and added value of patient and caregiver reports.

Frontiers in neurology·2026
Same author

Intrathecal IgM species as potential prognostic biomarkers in relapsing-remitting multiple sclerosis.

Multiple sclerosis and related disorders·2026

Genetic variations in the ELAVL4 gene were studied in Parkinson's disease (PD) patients. While not linked in US or Norwegian samples, specific ELAVL4 markers showed association with PD susceptibility in Irish patients, possibly due to a founder effect.

Area of Science:

  • Neurogenetics
  • Human Genetics
  • Epidemiology

Background:

  • Genetic variability in the ELAVL4 gene, located in the PARK10 locus, has been linked to age-at-onset (AAO) in Parkinson's disease (PD).
  • Previous associations were primarily observed in US-based Parkinson's disease cohorts.

Purpose of the Study:

  • To investigate the association of genetic variability in ELAVL4 with Parkinson's disease susceptibility and age-at-onset.
  • To replicate and extend previous findings in diverse case-control populations from Norway, the United States, and Ireland.

Main Methods:

  • Genotyping of five single-nucleotide polymorphisms (SNPs) within the ELAVL4 gene.
  • Case-control study design involving Norwegian, United States, and Irish participants.
  • Statistical analysis to assess the association between ELAVL4 markers, PD susceptibility, and age-at-onset.

Related Experiment Videos

Main Results:

  • No significant association was found between the examined ELAVL4 markers and PD susceptibility or age-at-onset in Norwegian or United States cohorts.
  • Two ELAVL4 markers, rs967582 and rs3902720, were significantly associated with increased susceptibility to Parkinson's disease in the Irish case-control sample.
  • The findings suggest a potential population-specific effect of ELAVL4 in Parkinson's disease.

Conclusions:

  • The association of ELAVL4 with Parkinson's disease susceptibility may be influenced by population-specific genetic factors, such as a Celtic-founder effect in the Irish population.
  • ELAVL4 is a potential susceptibility gene for Parkinson's disease in specific ethnic groups.
  • Further research is warranted to elucidate the role of ELAVL4 in Parkinson's disease pathogenesis across different ancestries.